Welcome to our dedicated page for Guardian Pharmacy Services SEC filings (Ticker: GRDN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Guardian Pharmacy Services, Inc. (NYSE: GRDN), a long-term care pharmacy services company based in Atlanta, Georgia. Through these filings, investors can review how Guardian reports its financial condition, results of operations, and other material events.
Guardian’s recent SEC activity includes multiple Current Reports on Form 8-K. These filings have covered topics such as quarterly financial results, reiteration of financial guidance and preliminary outlook, and the furnishing of investor presentations used at healthcare conferences and in meetings with analysts and other interested parties. Certain 8-Ks also describe lock-up agreements with holders of Class A and Class B common stock following the company’s initial public offering.
The company’s filings confirm that its Class A common stock, par value $0.001 per share, is registered under Section 12(b) of the Exchange Act and trades on the New York Stock Exchange under the symbol GRDN. Guardian uses its periodic reports, including the Annual Report on Form 10-K and Quarterly Reports on Form 10-Q (not reproduced here), to present GAAP financial statements and to discuss risk factors affecting its business.
Guardian also explains in its filings and related press releases how it uses non-GAAP measures such as Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, and Adjusted SG&A, and provides reconciliations to the most directly comparable GAAP measures in its full reports. These documents give additional context on how the company evaluates its core operating performance.
On this page, Stock Titan surfaces Guardian’s SEC filings as they are made available on EDGAR and pairs them with AI-generated summaries to help readers understand the key points of each document, from earnings-related 8-Ks to other material disclosures.
COSLER STEVEN D reported acquisition or exercise transactions in this Form 4 filing.
Guardian Pharmacy Services, Inc. director Steven D. Cosler received an equity grant of 4,028 shares of Class A common stock in the form of restricted stock units, awarded at no cash cost per share.
After this grant, Cosler directly holds 29,012 Class A common shares, reflecting a routine compensation-related award rather than an open-market purchase or sale.
Patchett Mary Sue reported acquisition or exercise transactions in this Form 4 filing.
Guardian Pharmacy Services, Inc. director Mary Sue Patchett received an equity grant of 4,028 shares of Class A Common Stock at a price of $0.00 per share. This award is in the form of restricted stock units that will be paid solely in Class A shares. After this grant, she directly holds 15,071 shares, showing her total reported equity stake following the award.
Guardian Pharmacy Services director LEWIS RANDALL J received an equity grant of 4,028 shares of Class A common stock on May 5, 2026. The award is structured as restricted stock units payable solely in shares of Class A common stock and carries no cash exercise price.
After this grant, the director holds 15,071 shares directly. This is a compensation-related award rather than an open-market purchase or sale, so it reflects routine equity-based compensation rather than a trading decision.
Guardian Pharmacy Services, Inc. reported results from its 2026 Annual Meeting of Stockholders held on May 5, 2026. Stockholders elected Class II directors John Ackerman and Randall Lewis to terms running until the 2029 annual meeting.
Both nominees received over 44.6 million votes "for," with additional broker non-votes recorded. Stockholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers and selected a one-year frequency for future advisory votes on executive pay. In addition, stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for 2026.
Guardian Pharmacy Services, Inc. filed an automatic shelf registration statement to permit the offering, issuance and resale of its Class A common stock from time to time after effectiveness. The prospectus also contemplates resales by identified selling stockholders; the company states it will not receive proceeds from shares sold by those selling stockholders.
The prospectus describes the company, its business serving approximately 207,000 residents through 61 pharmacies (54 full-service) across 38 states as of March 31, 2026, and discloses capital structure and transfer/conversion features of Class A and Class B common stock.
Guardian Pharmacy Services, Inc. reported solid Q1 2026 growth, with revenue rising to $336.6M from $329.3M, a 2.2% increase. Net income grew to $13.5M from $9.3M, and diluted EPS rose to $0.21 from $0.15, reflecting margin expansion.
Cost of goods sold fell to $260.3M, or 77.3% of revenue, helped by lower product costs under the Inflation Reduction Act, lifting gross profit to $76.3M. Adjusted EBITDA increased to $29.8M, or 8.8% of revenue.
The company ended March 31, 2026 with $64.9M in cash and no borrowings under its $40M credit facility. It also converted 13.5M Class B shares into Class A and executed a Q1 2026 follow-on offering in which 1.02M Class A shares were sold and repurchased for cancellation without changing shares outstanding.
Guardian Pharmacy Services, Inc. reported stronger first quarter 2026 results, with higher profitability and raised guidance. Revenue for the quarter ended March 31, 2026 grew to $336.6 million from $329.3 million a year earlier, while net income attributable to the company increased to $13.3 million from $9.4 million. Adjusted EBITDA rose to $29.8 million, and net income and Adjusted EBITDA margins improved to 4.0% and 8.8%, respectively.
Management highlighted double-digit Adjusted EBITDA growth, 10% growth in residents served and prescription volumes, and stable margins despite pricing resets from the Inflation Reduction Act. Full-year 2026 revenue guidance remains $1.40–$1.42 billion, while Adjusted EBITDA guidance was raised to $123–$127 million, reflecting about $3 million of discrete IRA-related and payor benefits.
In March 2026, Guardian completed a non-dilutive secondary offering of 6.9 million Class A shares that increased public float and trading liquidity, with no proceeds retained and no change in total Class A shares outstanding. The company also filed a new shelf registration statement but states it currently has no plans to use it.
FMR LLC reported beneficial ownership of 2,359,356.71 shares of Class A Common Stock of Guardian Pharmacy Services Inc, representing 6.5% of the class as of 03/31/2026. The filing shows sole voting power of 2,357,526 shares and sole dispositive power of 2,359,356.71 shares. The report was signed under a power of attorney and references an Exhibit 99 and a 13d-1(k)(1) agreement.
Guardian Pharmacy Services, Inc. reported the initial holdings of Senior Vice President of Sales Richard Eakins. He directly holds 98,878 shares of Class A common stock and 36,052 shares of Class B common stock that automatically convert into Class A common stock on September 27, 2026 on a one-for-one basis.
He also holds a stock option for 25,000 shares of Class A common stock with a $32.59 exercise price that vests in full on March 13, 2029. Footnotes state his position also includes 5,063 and 4,476 restricted stock units that will settle in Class A shares upon vesting in 2028 and 2029.
Guardian Pharmacy Services, Inc. executive William Franklin Mudd, Senior Vice President of Finance, filed an initial statement of ownership as a reporting insider. He directly holds 98,465 shares of Class A common stock and 38,282 shares of Class B common stock that convert into Class A on September 27, 2026 on a one-for-one basis.
He also holds stock options covering 25,000 shares of Class A common stock with a $34.59 exercise price, vesting and becoming exercisable in full on February 11, 2029. In addition, his position includes 7,594 and 4,476 restricted stock units that vest on February 14, 2028 and March 1, 2029, respectively, each settling one-for-one in Class A shares.